AignosticsNEW

Aignostics is a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health that develops AI-powered solutions for tissue-based precision medicine. The platform utilizes advanced machine learning algorithms to analyze complex histopathological tissue samples with high precision at cellular and molecular levels. This enables pharmaceutical and biotech companies to accelerate biomarker discovery and streamline clinical trials.

The technology transforms unstructured digital pathology whole-slide images into structured, highly quantifiable data points. Using specialized deep learning models, complex tumor microenvironments, cell-to-cell interactions, and specific tissue patterns can be automatically identified and evaluated. This provides deeper insights into disease mechanisms than traditional manual microscopy can deliver.

Aignostics' applications range from translational research and drug development to the creation of companion diagnostics. By integrating multimodal AI models, tissue analysis becomes more consistent, highly reproducible, and significantly faster, aiding in the development of novel targeted cancer therapies.

• AI-Powered Histopathology Analysis — Automated segmentation and classification of tissue structures and cell types in high-resolution Whole Slide Images (WSI). The AI models detect subtle pathological nuances with high accuracy.
• Biomarker Discovery & Quantification — Identification and mathematical validation of novel spatial biomarkers within the tumor microenvironment. This helps researchers define patient subgroups for targeted therapies.
• Multimodal Data Integration — Combines digital pathology images with clinical data and omics datasets for comprehensive tissue sample evaluation. This yields holistic insights into disease progression and treatment response.

Pathologists, oncology researchers, and pharmaceutical or biotechnology enterprises seeking advanced AI and digital pathology for drug discovery.

A global pharmaceutical company developing a novel immunotherapy for solid tumors requires detailed analysis of immune cell infiltration in the tumor microenvironment. Using the Aignostics platform, hundreds of digital tissue slides are automatically processed to map and quantify T-cells and tumor stroma. The research team rapidly receives objective, spatial quantitative data demonstrating statistically significant correlations with therapeutic response. This substantially accelerates the timeline for designing the upcoming clinical trial phase.

• Pathologists, oncology researchers, and pharmaceutical or biotechnology enterprises seeking advanced AI and digital pathology for drug discovery.
• A global pharmaceutical company developing a novel immunotherapy for solid tumors requires detailed analysis of immune cell infiltration in the tumor microenvironment.
• AI-Powered Histopathology Analysis: Automated segmentation and classification of tissue structures and cell types in high-resolution Whole Slide Images (WSI). The AI models detect subtle pathological nuances with high accuracy.
• Biomarker Discovery & Quantification: Identification and mathematical validation of novel spatial biomarkers within the tumor microenvironment. This helps researchers define patient subgroups for targeted therapies.
• Multimodal Data Integration: Combines digital pathology images with clinical data and omics datasets for comprehensive tissue sample evaluation. This yields holistic insights into disease progression and treatment response.

Not intended for individual medical practitioners seeking a low-cost, off-the-shelf image editing tool or immediate direct-to-consumer clinical diagnostic use without enterprise integration.

• contextflow — Paid · HQ: Wien, Austria · GDPR / EU
• deepc — Paid · HQ: München, Germany · GDPR / EU
• mediaire — Paid · HQ: Berlin, Germany · Unclear
• Vara — Paid · HQ: Berlin, Germany · GDPR / EU